Document Detail

The role of melatonin in acute myocardial infarction.
MedLine Citation:
PMID:  22652790     Owner:  NLM     Status:  MEDLINE    
Melatonin, a circadian hormone with marked antioxidant properties, has been shown to protect against ischemia-reperfusion myocardial damage, especially when administered during reperfusion period. Melatonin has cardioprotective properties via its direct free radical scavenging and its indirect antioxidant activity. Melatonin efficiently interacts with various reactive oxygen and reactive nitrogen species and it also upregulates antioxidant enzymes and downregulates pro-oxidant enzymes. In addition, melatonin demonstrated blood pressure lowering, lipid profile normalizing and anti-inflammatory properties. The lack of these cardioprotective effects due to insufficient melatonin levels might be associated with several cardiovascular pathologies including ischemic heart disease. Patients with acute coronary syndrome or after myocardial infarction were shown to have reduced nighttime melatonin levels and 6-sulfatoxymelatonin urinary excretion. These alterations might translate to increased cardiovascular risk observed in acute myocardial infarction patients with low melatonin levels; and a mutation in melatonin receptors might augment the risk for acute myocardial infarction. Therefore, it is expected that melatonin administration could play a clinically relevant role in the pharmacotherapy of ischemic heart disease; an assumption supported by low toxicity and high safety of melatonin.
Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Pablo Avanzas
Publication Detail:
Type:  Journal Article; Review     Date:  2012-06-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  17     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2012  
Date Detail:
Created Date:  2012-06-01     Completed Date:  2012-10-09     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2433-41     Citation Subset:  IM    
Hospital Universitario de Canarias, Department of Cardiology, Tenerife, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiotonic Agents / pharmacology
Circadian Rhythm / physiology
Coronary Artery Disease / etiology,  physiopathology
Melatonin / pharmacology,  physiology*,  therapeutic use
Models, Cardiovascular
Myocardial Infarction / drug therapy,  etiology*,  physiopathology*
Myocardial Reperfusion Injury / physiopathology,  prevention & control
Reg. No./Substance:
0/Cardiotonic Agents; 73-31-4/Melatonin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Angiotensinergic neurotransmission in the peripheral autonomic nervous system.
Next Document:  Compound selection for in vitro modeling of developmental neurotoxicity.